Investing
-
Aiming for an Epigenetics Edge, Chroma Raises $135M to Move Closer to the Clinic
GV led Chroma Medicine’s Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.
-
With New Kind of CAR, Cancer Startup Cargo Refuels With $200M for Cell Therapy Race
Cargo Therapeutics is developing CAR T-cell therapies that overcome ways cancers evade currently available treatments. True to its name, the startup’s approach involves putting more cargo and more complex cargo onto engineered T cells.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Blood Clotting Biotech Hemab Hauls In $135M to Drug Rare Bleeding Disorders
Hemab Therapeutics will apply its Series B financing toward clinical development of its lead drug candidate, a potential treatment for Glanzmann thrombasthenia. The capital will also support the rest its pipeline addressing rare bleeding and thrombotic diseases with no approved therapies.
-
Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
-
Pharma Returns Slump as Post-Pandemic Realities Set In, Deloitte Report Says
R&D spending rose in response to Covid-19, bringing with it higher expectations for returns on all biopharma investments. The once sky-high projections are coming down to Earth, with returns now in line with pre-pandemic levels, according to a new Deloitte report.
-
Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics
Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.
-
CDMO Startup Vector BioMed Launches to Fill Lentiviral Gap for Cell & Gene Therapies
Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
-
Biotech Financing Roundup: Belharra, NextPoint, Pathalys & More
Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.
-
Entact Bio Emerges With $81M to Play Matchmaker to Protein-Enhancing Drugs
Taking the opposite approach of targeted protein degradation, biotech company Entact Bio is developing medicines that stabilize proteins and even enhances their function. This approach that could apply to cancer and certain rare diseases, and Entact’s $81 million in Series A financing enables it to work on multiple programs in parallel.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
-
Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds
Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.
-
Autoimmune Biotech Zenas Gets $118M to Take Antibody Drug Into Phase 3
Zenas BioPharma’s Series B financing was the biggest one of the week. Other startups that emerged with new cash include Juvena Therapeutics, Sensorium Therapeutics, and NRG Therapeutics.
-
With Secreted Proteins Map, Juvena Finds Path to $41M for New Regenerative Meds
Juvena Therapeutics is developing secreted protein drugs built on new knowledge gleaned from proprietary technology that maps these proteins and the tissues in the body where they offer a regenerative effect. The startup’s lead program is in development for the muscle disorder myotonic dystrophy type 1.
-
Biotech Funding Roundup: HI-Bio’s Haul, Concerto’s Cash, Lusaris’s Launch & More
Emalex Biosciences raised $250 million, a Series D round of funding that was the biggest biotech financing of the past week. Other biotech startup that raised money include Alterome Therapeutics, hC Bioscience, and Novadip Bioscience.
-
For Neuro Biotech Lusaris, Depression Therapy Starts by Lifting the Tongue
Lusaris Therapeutics launched with $60 million for clinical development of a psychedelic depression drug it claims will be easier to dose and fast-acting. The company was formed and incubated by RA Capital Management, which led the startup’s Series A round of financing.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
